BRD9757

BRD9757 is a **highly potent and selective small molecule inhibitor of histone deacetylase 6 (HDAC6)**, with an IC50 of 30 nM for HDAC6 and high selectivity over other HDAC isoforms[1][3][5][7][9][11][13]. It acts by selectively increasing acetylated α-tubulin without affecting histone acetylation, making it a valuable research tool for studying epigenetic mechanisms and HDAC6-dependent processes. BRD9757 has demonstrated preclinical activity in cancer and HIV research models, such as latency reversal in HIV-1-infected T cell reservoirs[2][13]. *For research use only; not approved for clinical or therapeutic use*. It was originally reported by the Broad Institute[11].

Other names

N-Hydroxy-1-cyclopentene-1-carboxamideN-Hydroxy1-cyclopentene-1-carboxamideN-Hydroxy 1-cyclopentene-1-carboxamide